Health-care companies declined as concerns about AbbVie and Humana weighed. Shares of AbbVie plunged, losing more than 12% of their value after the drugmaker said participants in two mid-stage trials ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...

With rising demand and an ageing population, European healthcare systems are under strain. In the second article in our ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

Health-care companies declined as concerns about AbbVie and Humana weighed. Shares of AbbVie plunged, losing more than 12% of their value after the drugmaker said participants in two mid-stage ...

AbbVie (ABBV – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Geoff Meacham ...

ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY ...

Terence Flynn, an analyst from Morgan Stanley, reiterated the Buy rating on AbbVie (ABBV – Research Report). The associated price target ...

In this article, we are going to take a look at where AbbVie Inc. (NYSE:ABBV) stands against the other pharma stocks.